Basic Information
LncRNA/CircRNA Name | CASC2 |
Synonyms | CASC2, C10orf5 |
Region | GRCh38_10:118046279-118210153 |
Ensemble | ENSG00000177640 |
Refseq | NR_026939 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | gastric cancer |
ICD-0-3 | C16 |
Methods | qPCR, Luciferase reporter assay, other |
Sample | gastric cancer tissues and cell lines (BGC823 and SGC7901) and their DDP-resistant cell lines (BGC823/DDP and SGC7901/DDP) |
Expression Pattern | down-regulated |
Function Description | Gastric cancer patients with low CASC2 expression levels had a poor prognosis. CASC2 overexpression enhanced DDP sensitivity of BGC823/DDP and SGC7901/DDP cells. Conversely, CASC2 knockdown weakened the response of BGC823 and SGC7901 to DPP. Moreover, CASC2 could function as a miR-19a sponge. miR-19a inhibition could overcome DDP resistance in BGC823/DDP and SGC7901/DDP cells, while miR-19a overexpression led to DDP resistance in BGC823 and SGC7901 cells. Notably, miR-19a overexpression counteracted CASC2 up-regulation-mediated enhancement in DDP sensitivity of BGC823/DDP and SGC7901/DDP cells. |
Pubmed ID | 30372881 |
Year | 2018 |
Title | Down-regulation of CASC2 Contributes to Cisplatin Resistance in Gastric Cancer by Sponging miR-19a |
External Links
Links for CASC2 | GenBank HGNC NONCODE |
Links for gastric cancer | OMIM COSMIC |